About Us
- Contact Us
Our Technology
Our Science
- Pipeline
- Advantages of Gylden’s Candidates
News and Events
Menu Menu

You are here: Home1 / Conferences2 / Emergex T cell Chikungunya Vaccine: A Model for Emergex’s Synthetic...

Emergex T cell Chikungunya Vaccine: A Model for Emergex’s Synthetic T Cell Vaccine Platform as a Solution to Combat Alphaviruses Supporting Biothreat Preparedness

13th February 2025

Share this entry

Share on Facebook
Share on Twitter
Share on Pinterest
Share on LinkedIn
Share on Tumblr
Share on Vk
Share on Reddit
Share by Mail

/wp-content/uploads/2024/10/CompanyName-300x300.png 0 0 gatekeeper /wp-content/uploads/2024/10/CompanyName-300x300.png gatekeeper2025-02-13 08:09:312025-03-19 09:58:09Emergex T cell Chikungunya Vaccine: A Model for Emergex’s Synthetic T Cell Vaccine Platform as a Solution to Combat Alphaviruses Supporting Biothreat Preparedness

© Gylden Pharma

Website maintained by Digital Trading

Contact Us

Discovery of Novel Translated lncRNAs as Biomarkers in Colorectal Cancer Through...Progressing Next-Generation Vaccines using Hollow Microneedle Delivery – Results...